Sigma Planning’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
Other funds holding NBIX
Sigma Planning's NBIX Position: Q3 2026 in Review
Sigma Planning sold out of Neurocrine Biosciences (NBIX) in Q3 2026, closing a stake of 10,008 shares — an estimated $1.69M sold.
Sigma Planning first reported a position in NBIX in Q4 2017 and held it in 8 quarters. The position peaked at $1.69M in Q2 2026. 630 funds tracked by Wall St. Rank hold NBIX as of Q3 2026.
- Sigma Planning reported no remaining Neurocrine Biosciences position as of Q3 2026 after selling out during the quarter.
- Sigma Planning sold 10,008 Neurocrine Biosciences shares in Q3 2026, an estimated $1.69M.
- Sigma Planning first reported a position in Neurocrine Biosciences in Q4 2017 and held it in 8 quarters.
- Sigma Planning's Neurocrine Biosciences position peaked at $1.69M in Q2 2026.
- 630 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2026.
Based on Sigma Planning's 13F filing for Q3 2026, filed 23 Oct 2026.